about
Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of PennsyPlasma apolipoprotein A1 as a biomarker for Parkinson diseaseCognitive impairment and PD patients' capacity to consent to research.People with Parkinson's disease and normal MMSE score have a broad range of cognitive performanceThe Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's diseasePiloting the NPF data-driven quality improvement initiative.PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson diseaseMotor phenotype of LRRK2 G2019S carriers in early-onset Parkinson diseaseDesign of comprehensive Alzheimer's disease centers to address unmet national needs.Local institutional review board (IRB) review of a multicenter trial: local costs without local context.Treatment disparities in Parkinson's disease.Racial differences in the diagnosis of Parkinson's diseaseNovel CSF biomarkers for Alzheimer's disease and mild cognitive impairmentPremotor Parkinson's disease: clinical features, detection, and prospects for treatment.Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's diseaseQuestionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale.Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled studyAssociation between cognition and function in patients with Parkinson disease with and without dementia.Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease.Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control studyImaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities.Delayed Parkinson's disease diagnosis among African-Americans: the role of reporting of disability.Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database.Update on Parkinson disease.Building an integrated neurodegenerative disease database at an academic health center.Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.The organization of narrative discourse in Lewy body spectrum disorder.Screening questionnaires for parkinsonism: a systematic reviewDifficulty processing temporary syntactic ambiguities in Lewy body spectrum disorder.Development of quality of care indicators for Parkinson's disease.Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest.Longitudinal study of normal cognition in Parkinson disease.Impairments of speech fluency in Lewy body spectrum disorderGenetic influences on cognitive decline in Parkinson's disease.Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study.
P50
Q30250276-DA9AE57D-4168-4D31-A675-2ACBBFF5EB95Q30538175-A1952970-7E07-40DD-9BC0-097D19D9476BQ30544798-93B0FA71-90B1-4AE0-AA21-082C6537C389Q30570253-D49348A1-172B-4796-804B-754044472116Q30586896-F1F6D39F-6230-475D-A408-63321654112EQ30736054-F07D2BF5-20F8-4D31-8B3F-F81BDF5A132CQ33627149-3C1940AD-4253-43FD-836E-78A9478B3B60Q33637285-C3037488-314F-4711-8E59-8EB38103D5DBQ33666297-1B510860-F95D-4EA3-ACA5-EB9061B17651Q33698810-E33E225D-95FC-4F8E-816F-DE8471C1A2A3Q33723751-3B542C26-EF08-4058-89CE-252D1929EB15Q33742825-EA3F59F0-ED3F-49A6-A150-FE67333A5465Q33764475-4D3A49B5-FED4-4DA2-BA19-CF2249178658Q33796430-B6120497-E137-4736-A5F9-1EFB834433B6Q33806319-0DD11664-9B45-455A-95A1-272FDB9CD2BDQ33894316-BC6703BB-7DE4-48A0-8D44-5E17263D1097Q34015541-77A16073-772F-4BBE-B1B0-22F1182A1F31Q34080479-EC6BE8D8-CE47-4678-8073-82B093574120Q34089056-22D1211B-8207-4EE7-8781-23DEA16F6226Q34135756-4997930D-EF1D-4D68-97BC-243D39F99CC8Q34235570-29E3C70E-BD14-499B-B08A-6E3F280164F7Q34235667-41EBD556-AA02-492D-B4DF-B464C7B4D828Q34315258-CFACA1E6-D6E1-46E0-A142-1148F2392D3FQ34538553-23B31E23-24F0-4485-A650-58490001EE42Q34553777-EEC3C175-3092-49AA-AEBC-6C3F026740E0Q34666836-D47D01E7-B25C-4D43-9089-06AD35971B1DQ34985164-EE24CB7E-934A-4F34-82F4-38F28A0EC46CQ35071880-ECF6664A-EA30-4430-B1F6-0B8FCAE75F88Q35106568-EC1FF07E-FD97-407B-BBCA-B77A37D2F13FQ35134846-4367E5D4-BB41-4E25-B533-673DE0C1FB63Q35161892-D62FF942-A9E2-4BCC-A4A6-CC8759AF5F83Q35184421-A48105E7-EB6C-4EB3-8263-DE9054BA453CQ35659470-D6528E12-D528-435D-9B12-7700A83EE720Q35661275-5BFB557F-740C-403D-AC19-84A51B4B3AAEQ35673294-ADFD686D-F4E9-4F18-A189-1C09BF8246BEQ35758762-F3B1DE3A-7C90-42A4-8EBF-AD526E11FBC0Q35771313-DA46687F-6288-4CAD-86B5-1DA6E8ABE106Q35823236-7734B0A5-46C6-4791-921A-B738E22E9F59Q35881786-DD658FC8-CA25-4DE2-8C47-6FF0E59B2EC5Q35897974-509E378A-029A-4DD8-8F48-C718275D2BAC
P50
name
Andrew Siderowf
@ast
Andrew Siderowf
@en
Andrew Siderowf
@nl
type
label
Andrew Siderowf
@ast
Andrew Siderowf
@en
Andrew Siderowf
@nl
prefLabel
Andrew Siderowf
@ast
Andrew Siderowf
@en
Andrew Siderowf
@nl